EP1487417A4
(de)
|
2001-09-17 |
2010-03-17 |
Glaxo Group Ltd |
Medikamentöse trockenpulver-formulierungen
|
TWI249515B
(en)
*
|
2001-11-13 |
2006-02-21 |
Theravance Inc |
Aryl aniline beta2 adrenergic receptor agonists
|
WO2003042160A1
(en)
*
|
2001-11-13 |
2003-05-22 |
Theravance, Inc. |
Aryl aniline beta-2 adrenergic receptor agonists
|
EP1507754A1
(de)
|
2002-05-28 |
2005-02-23 |
Theravance, Inc. |
Alkoxy aryl beta-2 adrenergen rezeptoragonisten
|
TW200409746A
(en)
*
|
2002-07-26 |
2004-06-16 |
Theravance Inc |
Crystalline β2 adrenergic receptor agonist
|
US6844362B2
(en)
|
2002-10-11 |
2005-01-18 |
Pfizer Inc |
Indole derivatives useful for the treatment of diseases
|
EP1622875B1
(de)
|
2003-05-08 |
2009-12-02 |
Theravance, Inc. |
Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists
|
TW200510277A
(en)
|
2003-05-27 |
2005-03-16 |
Theravance Inc |
Crystalline form of β2-adrenergic receptor agonist
|
US7067541B2
(en)
|
2003-06-04 |
2006-06-27 |
Pfizer Inc |
2-amino-pyridine derivatives useful for the treatment of diseases
|
US7375100B2
(en)
|
2003-06-04 |
2008-05-20 |
Pfizer Inc |
2-amino-pyridine derivatives useful for the treatment of diseases
|
GB0316290D0
(en)
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
ES2449718T3
(es)
|
2003-08-11 |
2014-03-20 |
Glaxo Group Limited |
Inhalador de dosis farmacéutica medida y procedimiento relacionados con el mismo
|
TW200526547A
(en)
|
2003-09-22 |
2005-08-16 |
Theravance Inc |
Amino-substituted ethylamino β2 adrenergic receptor agonists
|
TW200531692A
(en)
|
2004-01-12 |
2005-10-01 |
Theravance Inc |
Aryl aniline derivatives as β2 adrenergic receptor agonists
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
DK1708992T3
(da)
|
2004-01-22 |
2007-11-05 |
Pfizer |
Sulfonamidderivater til behandling af sygdomme
|
EP1577291A1
(de)
*
|
2004-03-17 |
2005-09-21 |
Pfizer Limited |
Phenylethanolamin-Derivate als Beta-2 Agonisten
|
EA200601510A1
(ru)
*
|
2004-03-17 |
2007-04-27 |
Пфайзер Инк. |
Производные фенилэтаноламина в качестве бета-2-агонистов
|
GB0425054D0
(en)
*
|
2004-03-23 |
2004-12-15 |
Pfizer Ltd |
Formamide derivatives for the treatment of diseases
|
BRPI0507877A
(pt)
*
|
2004-03-23 |
2007-07-24 |
Pfizer |
derivados de formamida, composição farmacêutica, uso dos mesmos e combinação
|
CA2561400A1
(en)
*
|
2004-04-02 |
2005-10-13 |
Glaxo Group Limited |
Chemical process and new crystalline form
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
AR049384A1
(es)
|
2004-05-24 |
2006-07-26 |
Glaxo Group Ltd |
Derivados de purina
|
US20080039495A1
(en)
*
|
2004-06-03 |
2008-02-14 |
Linsell Martin S |
Diamine Beta2 Adrenergic Receptor Agonists
|
EP1778638A1
(de)
|
2004-07-21 |
2007-05-02 |
Theravance, Inc. |
Adrenergische diaryl ether beta2-rezeptoragonisten
|
GB0418045D0
(en)
|
2004-08-12 |
2004-09-15 |
Glaxo Group Ltd |
Compounds
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
WO2006066907A1
(en)
*
|
2004-12-21 |
2006-06-29 |
Glaxo Group Limited |
Pharmaceutical formulations
|
EP1841780B1
(de)
|
2005-01-10 |
2011-07-27 |
Glaxo Group Limited |
Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
|
PE20061351A1
(es)
|
2005-03-25 |
2007-01-14 |
Glaxo Group Ltd |
COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
ES2265276B1
(es)
|
2005-05-20 |
2008-02-01 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
US7994211B2
(en)
|
2005-08-08 |
2011-08-09 |
Argenta Discovery Limited |
Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
JP5006330B2
(ja)
|
2005-10-21 |
2012-08-22 |
ノバルティス アーゲー |
Il13に対するヒト抗体および治療的使用
|
TW200730498A
(en)
|
2005-12-20 |
2007-08-16 |
Glaxo Group Ltd |
Compounds
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
TW200745084A
(en)
*
|
2006-03-08 |
2007-12-16 |
Astrazeneca Ab |
Novel compounds
|
TW200745067A
(en)
|
2006-03-14 |
2007-12-16 |
Astrazeneca Ab |
Novel compounds
|
AU2007242851A1
(en)
|
2006-04-20 |
2007-11-01 |
Glaxo Group Limited |
Novel compounds
|
AR060607A1
(es)
|
2006-04-21 |
2008-07-02 |
Novartis Ag |
Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias.
|
GB0611587D0
(en)
|
2006-06-12 |
2006-07-19 |
Glaxo Group Ltd |
Novel compounds
|
CL2007001829A1
(es)
|
2006-06-23 |
2008-01-25 |
Smithkline Beecham Corp |
P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
|
ES2302447B1
(es)
*
|
2006-10-20 |
2009-06-12 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
TW200833670A
(en)
|
2006-12-20 |
2008-08-16 |
Astrazeneca Ab |
Novel compounds 569
|
ATE493174T1
(de)
|
2007-01-10 |
2011-01-15 |
Irm Llc |
Verbindungen und zusammensetzungen als kanal- aktivierende proteasehemmer
|
GB0702458D0
(en)
|
2007-02-08 |
2007-03-21 |
Astrazeneca Ab |
Salts 668
|
ES2306595B1
(es)
|
2007-02-09 |
2009-09-11 |
Laboratorios Almirall S.A. |
Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
|
US20100239551A1
(en)
|
2007-02-09 |
2010-09-23 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
PE20081889A1
(es)
|
2007-03-23 |
2009-03-05 |
Smithkline Beecham Corp |
Indol carboxamidas como inhibidores de ikk2
|
ES2361595T3
(es)
|
2007-05-07 |
2011-06-20 |
Novartis Ag |
Compuestos orgánicos.
|
ES2320961B1
(es)
|
2007-11-28 |
2010-03-17 |
Laboratorios Almirall, S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
|
CN101939054B
(zh)
|
2007-12-10 |
2014-10-29 |
诺华股份有限公司 |
有机化合物
|
BRPI0906838A2
(pt)
|
2008-01-11 |
2015-07-14 |
Novartis Ag |
Pirimidinas como inibidores de quinase
|
KR20160129109A
(ko)
|
2008-05-23 |
2016-11-08 |
아미라 파마슈티칼스 인코포레이티드 |
5-리폭시게나아제 활성화 단백질 억제제
|
US8163743B2
(en)
|
2008-06-05 |
2012-04-24 |
GlaxoGroupLimited |
4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
|
KR20110040818A
(ko)
|
2008-06-10 |
2011-04-20 |
노파르티스 아게 |
상피 나트륨 채널 차단제로서의 피라진 유도체
|
AU2009260899B2
(en)
|
2008-06-18 |
2012-02-23 |
Astrazeneca Ab |
Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
|
US8236786B2
(en)
|
2008-08-07 |
2012-08-07 |
Pulmagen Therapeutics (Inflammation) Limited |
Respiratory disease treatment
|
UY32297A
(es)
|
2008-12-22 |
2010-05-31 |
Almirall Sa |
Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
|
US8362064B2
(en)
|
2008-12-30 |
2013-01-29 |
Pulmagen Theraputics (Inflammation) Limited |
Sulfonamide compounds for the treatment of respiratory disorders
|
WO2010094643A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxo Group Limited |
Quinoline derivatives and their uses for rhinitis and urticaria
|
JP5656880B2
(ja)
|
2009-03-09 |
2015-01-21 |
グラクソ グループ リミテッドGlaxo Group Limited |
Pi3キナーゼの阻害剤としての4−オキサジアゾール−2−イル−インダゾール
|
US8354539B2
(en)
|
2009-03-10 |
2013-01-15 |
Glaxo Group Limited |
Indole derivatives as IKK2 inhibitors
|
EP2228368A1
(de)
|
2009-03-12 |
2010-09-15 |
Almirall, S.A. |
Verfahren zur Herstellung von 5-(2-{[6-(2,2-Difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxychinolin-2(1H)-on
|
JP2012520845A
(ja)
|
2009-03-17 |
2012-09-10 |
グラクソ グループ リミテッド |
Itk阻害剤として使用されるピリミジン誘導体
|
AU2010226604A1
(en)
|
2009-03-19 |
2011-10-13 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
|
WO2010107958A1
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20120029054A1
(en)
|
2009-03-19 |
2012-02-02 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
|
EP2408916A2
(de)
|
2009-03-19 |
2012-01-25 |
Merck Sharp&Dohme Corp. |
Rna-interferenz-vermittelte hemmung der genexpression von ctgf (connective tissue growth factor) unter verwendung von sina (short interfering nucleic acid)
|
US20120004282A1
(en)
|
2009-03-27 |
2012-01-05 |
Merck Sharp & Dohme Corp, |
RNA Interference Mediated Inhibition of the Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
JP2012521763A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたシグナル伝達性転写因子1(STAT1)遺伝子発現のRNA干渉媒介性阻害
|
EP2411516A1
(de)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
Rna-interferenz-vermittelte hemmung der genexpression von ask1 (apoptose-signalregulierende kinase 1) unter verwendung von sina (short interfering nucleic acid)
|
WO2010111490A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20120004281A1
(en)
|
2009-03-27 |
2012-01-05 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
EP2421834A1
(de)
|
2009-04-24 |
2012-02-29 |
Glaxo Group Limited |
Pyrazol- und triazolcarbonsäureamide als inhibitoren des crac-kanals
|
US8399436B2
(en)
|
2009-04-24 |
2013-03-19 |
Glaxo Group Limited |
N-pyrazolyl carboxamides as CRAC channel inhibitors
|
KR101771193B1
(ko)
|
2009-04-30 |
2017-09-05 |
글락소 그룹 리미티드 |
Pi3키나아제 억제제로서 옥사졸 치환된 인다졸
|
WO2010150014A1
(en)
|
2009-06-24 |
2010-12-29 |
Pulmagen Therapeutics (Inflammation) Limited |
5r- 5 -deuterated glitazones for respiratory disease treatment
|
CN102665715A
(zh)
|
2009-10-22 |
2012-09-12 |
沃泰克斯药物股份有限公司 |
治疗囊性纤维化和其他慢性疾病的组合物
|
GB0918924D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Azaindole derivatives
|
GB0918922D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminopyridine derivatives
|
GB0918923D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminothiazole derivatives
|
EP2507223A1
(de)
|
2009-12-03 |
2012-10-10 |
Glaxo Group Limited |
Benzpyrazolderivate als p13-kinasehemmer
|
US20120238559A1
(en)
|
2009-12-03 |
2012-09-20 |
Glaxo Group Limited |
Novel compounds
|
EP2507231A1
(de)
|
2009-12-03 |
2012-10-10 |
Glaxo Group Limited |
Indazolderivate als pi3-kinaseinhibitoren
|
US20120272951A1
(en)
|
2009-12-16 |
2012-11-01 |
3M Innovative Properties Company |
Formulations and methods for controlling mdi particle size delivery
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
GB201002243D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
GB201002224D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
WO2011110575A1
(en)
|
2010-03-11 |
2011-09-15 |
Glaxo Group Limited |
Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
GB201007203D0
(en)
|
2010-04-29 |
2010-06-16 |
Glaxo Group Ltd |
Novel compounds
|
WO2012032546A2
(en)
*
|
2010-09-08 |
2012-03-15 |
Cadila Healthcare Limited |
Process for the preparation of salmeterol and its intermediates
|
PL2614058T3
(pl)
|
2010-09-08 |
2015-12-31 |
Glaxosmithkline Ip Dev Ltd |
Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
WO2012035055A1
(en)
|
2010-09-17 |
2012-03-22 |
Glaxo Group Limited |
Novel compounds
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
ES2532213T3
(es)
|
2010-10-21 |
2015-03-25 |
Glaxo Group Limited |
Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias
|
EP2630127A1
(de)
|
2010-10-21 |
2013-08-28 |
Glaxo Group Limited |
Pyrazolverbindungen, gegen allergie-, entzündungs- und immunerkrankungen
|
GB201018124D0
(en)
|
2010-10-27 |
2010-12-08 |
Glaxo Group Ltd |
Polymorphs and salts
|
JP5959541B2
(ja)
|
2011-02-25 |
2016-08-02 |
ノバルティス アーゲー |
Trk阻害剤としてのピラゾロ[1,5−a]ピリジン
|
GB201104153D0
(en)
|
2011-03-11 |
2011-04-27 |
Glaxo Group Ltd |
Novel compounds
|
JP2014507458A
(ja)
|
2011-03-11 |
2014-03-27 |
グラクソ グループ リミテッド |
Sykインヒビターとしてのピリド[3,4−B]ピラジン誘導体
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
EP2755652B1
(de)
|
2011-09-16 |
2021-06-02 |
Novartis AG |
N-substituierte heterocyclische carboxamide
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
JP5886433B2
(ja)
|
2011-09-16 |
2016-03-16 |
ノバルティス アーゲー |
嚢胞性線維症処置のためのヘテロ環式化合物
|
EP2578570A1
(de)
|
2011-10-07 |
2013-04-10 |
Almirall, S.A. |
Neues Verfahren zur Herstellung von 5-(2-{[6-(2,2-Difluor-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxychinolin-2(1H)-on mittels neuen Synthesezwischenstoffen
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
EP2641900A1
(de)
|
2012-03-20 |
2013-09-25 |
Almirall, S.A. |
Neuartige polymorphe Kristallformen von 5-(2-{[6-(2,2-difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxychinolin-2(1H)-on, Heminapadisylat als Agonist des beta2-adrenergen Rezeptors
|
EP2647627A1
(de)
*
|
2012-04-02 |
2013-10-09 |
Almirall, S.A. |
Salze von 5-[(1r)-(2-{[4-(2,2-difluor-2-phenylethoxy)phenyl].ethyl}amino}-1- hydroxyethyl)-8-hydroxychinolin-2(1H)-on.
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
EP3057587A1
(de)
|
2013-10-17 |
2016-08-24 |
GlaxoSmithKline Intellectual Property Development Limited |
Pi3k-hemmers zur behandlung von atemwegserkrankungen
|
EP3057588A1
(de)
|
2013-10-17 |
2016-08-24 |
GlaxoSmithKline Intellectual Property Development Limited |
Pi3k-hemmers zur behandlung von atemwegserkrankungen
|
MX2016013983A
(es)
|
2014-04-24 |
2017-04-06 |
Novartis Ag |
Derivados de pirazina como inhibidores de fosfatidil-inositol-3-ci nasa.
|
WO2015162456A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
US10004732B2
(en)
|
2014-04-24 |
2018-06-26 |
Novartis Ag |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
WO2015173701A2
(en)
|
2014-05-12 |
2015-11-19 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pharmaceutical compositions for treating infectious diseases
|
GB201602527D0
(en)
|
2016-02-12 |
2016-03-30 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
JP2019524792A
(ja)
|
2016-08-08 |
2019-09-05 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
化合物
|
GB201706102D0
(en)
|
2017-04-18 |
2017-05-31 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
GB201712081D0
(en)
|
2017-07-27 |
2017-09-13 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
JP2022537667A
(ja)
|
2019-06-10 |
2022-08-29 |
ノバルティス アーゲー |
Cf、copd、及び気管支拡張症の治療のためのピリジン及びピラジン誘導体
|
EP4021572A1
(de)
|
2019-08-28 |
2022-07-06 |
Novartis AG |
Substituierte 1,3-phenylheteroarylderivate und ihre verwendung zur behandlung von krankheiten
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
|